Obstetrics and Gynecology · Jun 23, 2026
Vaginal Microbiome in Perimenopause and Postmenopause: Dysbiosis, Genitourinary Syndrome and Novel Therapeutic Approaches
By Şen S, Şen FG
The vaginal microbiome shifts dramatically across the menopausal transition, moving away from the -dominated states that characterize reproductive life toward high-diversity, often dysbiotic communities dominated by anaerobes and enteric organisms. Estrogen withdrawal drives this shift through a well-characterized metabolic cascade linking circulating hormone levels to epithelial glycogen deposition and, ultimately, to the acid-producing capacity of vaginal lactobacilli. Population data covering tens of thousands of women place the compositional inflection point near age 45, after which -dominated community state types (CSTs) decline sharply, and dysbiotic compositions become the postmenopausal norm. These microbiological changes form part of the pathophysiological substrate of genitourinary syndrome of menopause (GSM), a chronic condition affecting between 40% and 87% of postmenopausal women that encompasses genital, sexual, and urinary symptoms. We review current evidence on vaginal CSTs, the estrogen–glycogen– axis, age-specific dysbiosis patterns, and the clinical burden of GSM, drawing on recent meta-analyses, large cohort studies, and mechanistic animal data. Hormonal therapies – local estrogen, ospemifene, and intravaginal dehydroepiandrosterone (DHEA) – partially restore prevalence and reduce symptom burden, while nonhormonal options, including probiotics, energy-based devices, hyaluronic acid, and vaginal microbiome transplantation (VMT), address distinct needs with variable degrees of evidence. Microbiome-guided, personalized treatment selection represents the direction toward which this field is moving.